FPRXFIVE PRIME THERAPEUTICS, INC.

Nasdaq www.fiveprime.com


$ 38.00 $ 0.01 (0.03 %)    

Thursday, 15-Apr-2021 15:59:31 EDT
QQQ $ 486.52 $ 5.06 (1.05 %)
DIA $ 393.25 $ 1.83 (0.47 %)
SPY $ 548.30 $ 3.67 (0.67 %)
TLT $ 90.61 $ 0.70 (0.78 %)
GLD $ 215.57 $ -0.01 (0 %)
$ 38
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 2.61 - $ 38.90
1,006,601
na
1.77B
$ 1.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-22-2021 12-31-2020 10-K
2 11-03-2020 09-30-2020 10-Q
3 08-06-2020 06-30-2020 10-Q
4 05-07-2020 03-31-2020 10-Q
5 02-27-2020 12-31-2019 10-K
6 11-06-2019 09-30-2019 10-Q
7 08-08-2019 06-30-2019 10-Q
8 05-09-2019 03-31-2019 10-Q
9 02-26-2019 12-31-2018 10-K
10 11-06-2018 09-30-2018 10-Q
11 08-08-2018 06-30-2018 10-Q
12 05-08-2018 03-31-2018 10-Q
13 02-27-2018 12-31-2017 10-K
14 11-06-2017 09-30-2017 10-Q
15 08-08-2017 06-30-2017 10-Q
16 05-05-2017 03-31-2017 10-Q
17 02-24-2017 12-31-2016 10-K
18 11-04-2016 09-30-2016 10-Q
19 08-05-2016 06-30-2016 10-Q
20 05-06-2016 03-31-2016 10-Q
21 03-11-2016 12-31-2015 10-K
22 11-05-2015 09-30-2015 10-Q
23 08-07-2015 06-30-2015 10-Q
24 05-14-2015 03-31-2015 10-Q
25 03-18-2015 12-31-2014 10-K
26 11-12-2014 09-30-2014 10-Q
27 08-07-2014 06-30-2014 10-Q
28 05-12-2014 03-31-2014 10-Q
29 03-26-2014 12-31-2013 10-K
30 11-13-2013 09-30-2013 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 though-potential-bidders-moved-away-amgens-bid-for-five-prime-outlasted-15-suitors

Earlier this month, biotech giant Amgen Inc (NASDAQ: AMGN) 

 the-daily-biotech-pulse-medicinova-bags-barda-contract-lillys-covid-19-antibody-cocktail-data-bluebird-bio-refutes-blood-cancer-link

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitti...

 earnings-scheduled-for-march-10-2021

  Companies Reporting Before The Bell • BioDelivery Sciences Intl (NASDAQ:BDSI) is estimated to report quarterly earnings at ...

 earnings-outlook-for-five-prime-therapeutics

Five Prime Therapeutics (NASDAQ:FPRX) releases its next round of earnings this Wednesday, March 10. Get the latest predictions ...

 guggenheim-downgrades-five-prime-therapeutics-to-neutral-announces-38-price-target

Guggenheim analyst Etzer Darout downgrades Five Prime Therapeutics (NASDAQ:FPRX) from Buy to Neutral and announces $38 price...

 the-week-ahead-in-biotech-march-7-13-conference-presentations-and-more-earnings

Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light...

 the-daily-biotech-pulse-fulgents-big-quarter-gilead-awaits-fda-decision-apellis-winds-up-covid-19-study

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitti...

 jefferies-downgrades-five-prime-therapeutics-to-hold-announces-38-price-target

Jefferies analyst Eun Yang downgrades Five Prime Therapeutics (NASDAQ:FPRX) from Buy to Hold and announces $38 price target.

 82-biggest-movers-from-yesterday
82 Biggest Movers From Yesterday
03/05/2021 10:37:42

Gainers Five Prime Therapeutics, Inc. (NASDAQ: FPRX) shares surged 78.7% to close at $38.00 on Thursday after Amgen announc...

Core News & Articles

Toward the end of trading Thursday, the Dow traded down 1.07% to 30,935.46 while the NASDAQ fell 1.64% to 12,784.21. The S&...

Core News & Articles

Midway through trading Thursday, the Dow traded up 0.11% to 31,304.43 while the NASDAQ fell 0.05% to 12,990.83. The S&P als...

Core News & Articles

Gainers Five Prime Therapeutics, Inc. (NASDAQ: FPRX) shares jumped 78% to $37.85 after Amgen announced plans to acquire the...

Core News & Articles

Amgen Inc (NASDAQ: AMGN) 

Core News & Articles

    Thursday's morning session saw 237 companies set new 52-week highs.

Core News & Articles

Following the market opening Thursday, the Dow traded down 0.22% to 31,202.42 while the NASDAQ fell 1.6% to 12,790.20. The S&am...

Core News & Articles

Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Canc...